patient_id stringlengths 12 12 | record_id stringlengths 11 11 | cancer_type stringclasses 1
value | histology stringclasses 3
values | stage_at_diagnosis stringclasses 3
values | driver_mutation stringclasses 7
values | pd_l1_tps_percent int64 5 41 | tmb_mutations_per_mb float64 1.5 25 | age_at_diagnosis int64 38 90 | sex stringclasses 2
values | ecog_performance_status int64 0 4 | smoking_pack_years int64 0 111 | primary_tumor_size_cm float64 2 10 | metastatic_sites_count int64 0 11 | first_line_regimen stringclasses 6
values | overall_survival_months float64 4 83 | censored bool 2
classes | msi_status stringclasses 2
values | record_generation_timestamp stringdate 2026-03-15 05:35:56 2026-03-15 05:36:02 | synthetic_source stringclasses 1
value |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
ANODE_862258 | REC_0001101 | Non-small cell lung cancer | Adenocarcinoma | III | EGFR exon 19 deletion | 23 | 13.6 | 51 | male | 0 | 21 | 4.5 | 0 | osimertinib 80 mg daily | 48.5 | false | MSI-H | 2026-03-15T05:35:57.114121+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_133116 | REC_0001102 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 27 | 18.1 | 60 | male | 0 | 23 | 7 | 5 | osimertinib 80 mg daily | 9.5 | true | MSI-H | 2026-03-15T05:35:57.114356+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_598559 | REC_0001103 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 25 | 10.5 | 79 | female | 1 | 4 | 5.5 | 4 | osimertinib 80 mg daily | 12.2 | false | MSI-H | 2026-03-15T05:35:57.114587+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_811953 | REC_0001104 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 31 | 11.9 | 71 | female | 1 | 13 | 7.1 | 5 | sotorasib 960 mg daily | 12.6 | true | MSS | 2026-03-15T05:35:57.114818+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_380412 | REC_0001105 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR L858R | 28 | 14.1 | 85 | female | 2 | 14 | 6.2 | 2 | osimertinib 80 mg daily | 9 | false | MSI-H | 2026-03-15T05:35:57.115055+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_680911 | REC_0001106 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 21 | 10.4 | 70 | female | 2 | 0 | 4.8 | 5 | sotorasib 960 mg daily | 6.4 | true | MSI-H | 2026-03-15T05:35:57.115336+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_745280 | REC_0001107 | Non-small cell lung cancer | Adenocarcinoma | IVA | ALK fusion | 25 | 7.5 | 67 | female | 0 | 16 | 3.8 | 1 | alectinib 600 mg BID | 14 | false | MSS | 2026-03-15T05:35:57.115573+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_277444 | REC_0001108 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 25 | 9.9 | 65 | male | 1 | 25 | 5.7 | 3 | alectinib 600 mg BID | 13.3 | true | MSS | 2026-03-15T05:35:57.115803+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_796353 | REC_0001109 | Non-small cell lung cancer | Adenocarcinoma | IVA | ROS1 fusion | 20 | 10.1 | 87 | female | 1 | 17 | 4.5 | 2 | entrectinib 600 mg daily | 18.5 | false | MSI-H | 2026-03-15T05:35:57.116035+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_891768 | REC_0001110 | Non-small cell lung cancer | Adenocarcinoma | III | ALK fusion | 33 | 16.8 | 68 | female | 1 | 25 | 3.3 | 0 | alectinib 600 mg BID | 54.5 | false | MSS | 2026-03-15T05:35:57.116345+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_805467 | REC_0001111 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 34 | 5.1 | 62 | male | 0 | 27 | 5.8 | 7 | entrectinib 600 mg daily | 13.5 | true | MSS | 2026-03-15T05:35:57.116582+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_420697 | REC_0001112 | Non-small cell lung cancer | Adenocarcinoma | IVA | ROS1 fusion | 22 | 10.2 | 68 | female | 0 | 20 | 5 | 1 | entrectinib 600 mg daily | 19.1 | true | MSS | 2026-03-15T05:35:57.116814+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_169588 | REC_0001113 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 26 | 11.7 | 67 | female | 0 | 22 | 5.6 | 5 | entrectinib 600 mg daily | 8.3 | false | MSS | 2026-03-15T05:35:57.117050+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_825774 | REC_0001114 | Non-small cell lung cancer | Adenocarcinoma | IVB | None (PD-L1 high) | 23 | 10.2 | 80 | female | 2 | 11 | 6.5 | 7 | pembrolizumab 200 mg q3w | 11.6 | false | MSI-H | 2026-03-15T05:35:57.117288+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_349249 | REC_0001115 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None (PD-L1 high) | 26 | 7.4 | 51 | male | 0 | 46 | 5 | 3 | pembrolizumab 200 mg q3w | 10 | false | MSS | 2026-03-15T05:35:57.117521+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_476040 | REC_0001116 | Non-small cell lung cancer | Adenocarcinoma | III | EGFR L858R | 28 | 12.4 | 69 | female | 0 | 5 | 5.4 | 0 | osimertinib 80 mg daily | 11 | false | MSI-H | 2026-03-15T05:35:57.117752+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_600026 | REC_0001117 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 23 | 13.5 | 66 | male | 0 | 12 | 5.2 | 5 | entrectinib 600 mg daily | 12.3 | false | MSS | 2026-03-15T05:35:57.117988+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_166314 | REC_0001118 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None | 25 | 4.9 | 63 | male | 0 | 54 | 4.7 | 2 | carboplatin + paclitaxel + pembrolizumab | 21 | false | MSS | 2026-03-15T05:35:57.118219+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_591466 | REC_0001119 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 27 | 8.2 | 57 | female | 0 | 24 | 5.5 | 4 | alectinib 600 mg BID | 7.2 | false | MSS | 2026-03-15T05:35:57.118509+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_757971 | REC_0001120 | Non-small cell lung cancer | Adenocarcinoma | IVA | KRAS G12C | 28 | 14.9 | 66 | female | 1 | 15 | 6.3 | 1 | sotorasib 960 mg daily | 13.2 | false | MSS | 2026-03-15T05:35:57.118754+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_891197 | REC_0001121 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 29 | 11.2 | 63 | male | 1 | 10 | 5.8 | 5 | sotorasib 960 mg daily | 12.6 | false | MSS | 2026-03-15T05:35:57.119016+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_452793 | REC_0001122 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR exon 19 deletion | 18 | 12.8 | 73 | female | 1 | 20 | 5 | 1 | osimertinib 80 mg daily | 15.2 | false | MSS | 2026-03-15T05:35:57.119272+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_507829 | REC_0001123 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 22 | 6.4 | 66 | female | 1 | 6 | 4.6 | 4 | sotorasib 960 mg daily | 11.5 | false | MSS | 2026-03-15T05:35:57.119523+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_201416 | REC_0001124 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR L858R | 25 | 12.9 | 68 | female | 0 | 19 | 6.8 | 2 | osimertinib 80 mg daily | 19.1 | false | MSS | 2026-03-15T05:35:57.119778+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_701483 | REC_0001125 | Non-small cell lung cancer | Adenocarcinoma | IVA | KRAS G12C | 36 | 8.9 | 70 | female | 2 | 9 | 5.4 | 2 | sotorasib 960 mg daily | 16.3 | false | MSS | 2026-03-15T05:35:57.120020+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_498900 | REC_0001126 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 18 | 10.4 | 66 | male | 0 | 10 | 4.2 | 4 | entrectinib 600 mg daily | 14.9 | false | MSI-H | 2026-03-15T05:35:57.120316+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_884587 | REC_0001127 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 25 | 14.7 | 56 | female | 0 | 18 | 4.8 | 7 | osimertinib 80 mg daily | 17 | false | MSI-H | 2026-03-15T05:35:57.120569+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_326234 | REC_0001128 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 19 | 12.6 | 59 | female | 1 | 20 | 7.3 | 6 | entrectinib 600 mg daily | 7.8 | false | MSI-H | 2026-03-15T05:35:57.120811+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_237528 | REC_0001129 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 25 | 8.9 | 59 | male | 0 | 11 | 6.8 | 5 | entrectinib 600 mg daily | 14.7 | false | MSS | 2026-03-15T05:35:57.121047+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_116832 | REC_0001130 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 22 | 8.3 | 72 | female | 2 | 35 | 7.3 | 6 | osimertinib 80 mg daily | 4 | false | MSS | 2026-03-15T05:35:57.121280+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_527458 | REC_0001131 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 29 | 8.8 | 60 | male | 0 | 48 | 5 | 3 | carboplatin + paclitaxel + pembrolizumab | 14.2 | false | MSS | 2026-03-15T05:35:57.121514+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_519272 | REC_0001132 | Non-small cell lung cancer | Adenocarcinoma | IVA | ROS1 fusion | 27 | 6.9 | 55 | male | 1 | 17 | 5 | 2 | entrectinib 600 mg daily | 14.5 | true | MSS | 2026-03-15T05:35:57.121845+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_555768 | REC_0001133 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 19 | 17.9 | 75 | male | 1 | 27 | 3.3 | 7 | osimertinib 80 mg daily | 9.3 | false | MSS | 2026-03-15T05:35:57.122089+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_290541 | REC_0001134 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 22 | 11.8 | 67 | female | 0 | 11 | 4.1 | 7 | osimertinib 80 mg daily | 14.4 | false | MSS | 2026-03-15T05:35:57.122322+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_937339 | REC_0001135 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None | 27 | 6.2 | 50 | male | 0 | 27 | 3.5 | 2 | carboplatin + paclitaxel + pembrolizumab | 15.9 | false | MSS | 2026-03-15T05:35:57.122557+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_199694 | REC_0001136 | Non-small cell lung cancer | Large cell carcinoma | IVA | None (PD-L1 high) | 25 | 7.9 | 63 | male | 1 | 14 | 3.8 | 2 | pembrolizumab 200 mg q3w | 22.8 | false | MSS | 2026-03-15T05:35:57.122788+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_511815 | REC_0001137 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None | 20 | 6.6 | 79 | female | 2 | 61 | 3.6 | 1 | carboplatin + paclitaxel + pembrolizumab | 17.6 | false | MSS | 2026-03-15T05:35:57.123023+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_797150 | REC_0001138 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 22 | 13.3 | 76 | female | 2 | 11 | 4.7 | 5 | sotorasib 960 mg daily | 6.7 | true | MSI-H | 2026-03-15T05:35:57.123258+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_981168 | REC_0001139 | Non-small cell lung cancer | Adenocarcinoma | IVA | KRAS G12C | 23 | 13.9 | 65 | male | 0 | 8 | 6.8 | 1 | sotorasib 960 mg daily | 21.7 | true | MSI-H | 2026-03-15T05:35:57.123494+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_586399 | REC_0001140 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None (PD-L1 high) | 29 | 5.7 | 64 | male | 1 | 40 | 5.6 | 2 | pembrolizumab 200 mg q3w | 15 | false | MSS | 2026-03-15T05:35:57.123726+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_132670 | REC_0001141 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR exon 19 deletion | 22 | 6 | 61 | female | 0 | 15 | 5.1 | 2 | osimertinib 80 mg daily | 26.6 | false | MSS | 2026-03-15T05:35:57.123958+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_404633 | REC_0001142 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 13 | 7.9 | 72 | male | 2 | 49 | 5.4 | 7 | carboplatin + paclitaxel + pembrolizumab | 19.7 | false | MSS | 2026-03-15T05:35:57.124243+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_869702 | REC_0001143 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 16 | 5.8 | 77 | male | 1 | 0 | 4.2 | 6 | carboplatin + paclitaxel + pembrolizumab | 14 | true | MSS | 2026-03-15T05:35:57.124483+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_100078 | REC_0001144 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 23 | 12.6 | 72 | female | 1 | 12 | 6.2 | 5 | alectinib 600 mg BID | 8.5 | false | MSI-H | 2026-03-15T05:35:57.124716+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_567340 | REC_0001145 | Non-small cell lung cancer | Large cell carcinoma | IVA | None (PD-L1 high) | 26 | 4.4 | 59 | female | 1 | 20 | 4.7 | 2 | pembrolizumab 200 mg q3w | 20.7 | false | MSS | 2026-03-15T05:35:57.125005+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_575751 | REC_0001146 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR exon 19 deletion | 23 | 11.1 | 81 | female | 0 | 15 | 3.9 | 2 | osimertinib 80 mg daily | 27.9 | true | MSS | 2026-03-15T05:35:57.125243+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_174271 | REC_0001147 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 21 | 15.7 | 77 | female | 3 | 25 | 6.1 | 4 | osimertinib 80 mg daily | 7.1 | false | MSI-H | 2026-03-15T05:35:57.125481+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_287540 | REC_0001148 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 22 | 4.4 | 64 | female | 1 | 52 | 5.1 | 6 | carboplatin + paclitaxel + pembrolizumab | 9.4 | false | MSS | 2026-03-15T05:35:57.125716+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_604832 | REC_0001149 | Non-small cell lung cancer | Adenocarcinoma | III | ALK fusion | 32 | 12.3 | 75 | female | 2 | 9 | 7.2 | 0 | alectinib 600 mg BID | 31.3 | false | MSI-H | 2026-03-15T05:35:57.125949+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_119701 | REC_0001150 | Non-small cell lung cancer | Large cell carcinoma | IVA | None (PD-L1 high) | 22 | 5.1 | 67 | female | 1 | 11 | 5.2 | 2 | pembrolizumab 200 mg q3w | 22.1 | true | MSS | 2026-03-15T05:35:57.126179+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_185239 | REC_0001151 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR L858R | 25 | 6.5 | 54 | male | 0 | 8 | 5.3 | 1 | osimertinib 80 mg daily | 27.8 | true | MSS | 2026-03-15T05:35:57.126413+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_578707 | REC_0001152 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 23 | 21.3 | 76 | female | 2 | 20 | 5.6 | 5 | sotorasib 960 mg daily | 9.4 | true | MSS | 2026-03-15T05:35:57.126644+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_826839 | REC_0001153 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 25 | 13.4 | 72 | female | 1 | 16 | 5.6 | 7 | osimertinib 80 mg daily | 9 | false | MSI-H | 2026-03-15T05:35:57.126875+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_154055 | REC_0001154 | Non-small cell lung cancer | Adenocarcinoma | IVA | ALK fusion | 24 | 13.2 | 58 | male | 1 | 20 | 6.6 | 1 | alectinib 600 mg BID | 15.5 | false | MSS | 2026-03-15T05:35:57.127107+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_543100 | REC_0001155 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 17 | 15.4 | 67 | female | 1 | 20 | 6.3 | 5 | sotorasib 960 mg daily | 11.1 | false | MSS | 2026-03-15T05:35:57.127339+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_640214 | REC_0001156 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 28 | 12.4 | 64 | male | 1 | 2 | 5.9 | 6 | osimertinib 80 mg daily | 10.6 | false | MSI-H | 2026-03-15T05:35:57.127574+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_119432 | REC_0001157 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 27 | 11.6 | 63 | male | 1 | 14 | 5.5 | 4 | entrectinib 600 mg daily | 8.8 | false | MSS | 2026-03-15T05:35:57.127809+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_655659 | REC_0001158 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR L858R | 26 | 15.2 | 68 | female | 1 | 14 | 6.2 | 2 | osimertinib 80 mg daily | 24.3 | true | MSS | 2026-03-15T05:35:57.128132+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_804353 | REC_0001159 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 31 | 12.8 | 61 | female | 1 | 18 | 5.5 | 7 | osimertinib 80 mg daily | 8.2 | false | MSI-H | 2026-03-15T05:35:57.128378+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_733018 | REC_0001160 | Non-small cell lung cancer | Large cell carcinoma | IVA | None (PD-L1 high) | 20 | 5.2 | 59 | male | 0 | 25 | 5.4 | 2 | pembrolizumab 200 mg q3w | 4 | true | MSS | 2026-03-15T05:35:57.128611+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_313847 | REC_0001161 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None | 29 | 7.1 | 75 | female | 1 | 16 | 6.2 | 2 | carboplatin + paclitaxel + pembrolizumab | 16.4 | false | MSS | 2026-03-15T05:35:57.128845+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_509327 | REC_0001162 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 19 | 6.6 | 73 | male | 1 | 44 | 3.5 | 4 | carboplatin + paclitaxel + pembrolizumab | 11.9 | true | MSS | 2026-03-15T05:35:57.129077+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_797686 | REC_0001163 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 28 | 12.1 | 73 | female | 2 | 23 | 4.7 | 8 | alectinib 600 mg BID | 7.2 | true | MSS | 2026-03-15T05:35:57.129313+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_397699 | REC_0001164 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR exon 19 deletion | 21 | 13.3 | 59 | female | 1 | 24 | 6.3 | 1 | osimertinib 80 mg daily | 14.2 | true | MSI-H | 2026-03-15T05:35:57.129546+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_310607 | REC_0001165 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 22 | 6.8 | 59 | female | 1 | 38 | 4.7 | 4 | carboplatin + paclitaxel + pembrolizumab | 12.2 | false | MSS | 2026-03-15T05:35:57.129777+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_511157 | REC_0001166 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR exon 19 deletion | 22 | 12.9 | 74 | female | 1 | 6 | 6 | 1 | osimertinib 80 mg daily | 26.8 | false | MSI-H | 2026-03-15T05:35:57.130014+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_516987 | REC_0001167 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 33 | 20.4 | 54 | male | 0 | 14 | 5.6 | 6 | alectinib 600 mg BID | 14.1 | true | MSI-H | 2026-03-15T05:35:57.130251+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_449370 | REC_0001168 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 27 | 10.1 | 68 | female | 0 | 21 | 4.2 | 6 | sotorasib 960 mg daily | 8.2 | false | MSS | 2026-03-15T05:35:57.130487+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_855540 | REC_0001169 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 20 | 11.9 | 51 | female | 0 | 15 | 4.5 | 6 | osimertinib 80 mg daily | 9.3 | false | MSS | 2026-03-15T05:35:57.130723+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_590046 | REC_0001170 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 23 | 12.2 | 57 | female | 0 | 18 | 4.1 | 8 | osimertinib 80 mg daily | 7.9 | false | MSI-H | 2026-03-15T05:35:57.130960+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_442461 | REC_0001171 | Non-small cell lung cancer | Adenocarcinoma | IVA | ROS1 fusion | 18 | 10.4 | 62 | male | 0 | 18 | 5.3 | 1 | entrectinib 600 mg daily | 28 | false | MSS | 2026-03-15T05:35:57.131241+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_667674 | REC_0001172 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR L858R | 25 | 9.2 | 75 | female | 1 | 10 | 5.9 | 2 | osimertinib 80 mg daily | 14.3 | true | MSS | 2026-03-15T05:35:57.131474+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_649881 | REC_0001173 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 11 | 20.1 | 69 | male | 0 | 17 | 3.9 | 4 | alectinib 600 mg BID | 18.6 | false | MSI-H | 2026-03-15T05:35:57.131709+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_703778 | REC_0001174 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 24 | 11.4 | 80 | female | 1 | 23 | 4.6 | 2 | alectinib 600 mg BID | 19.4 | false | MSS | 2026-03-15T05:35:57.131942+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_614949 | REC_0001175 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 19 | 16 | 67 | female | 1 | 10 | 4.6 | 4 | sotorasib 960 mg daily | 11.2 | false | MSS | 2026-03-15T05:35:57.132203+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_510270 | REC_0001176 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None | 32 | 1.9 | 70 | female | 2 | 30 | 7 | 1 | carboplatin + paclitaxel + pembrolizumab | 9.2 | false | MSS | 2026-03-15T05:35:57.132433+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_175503 | REC_0001177 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 21 | 9.5 | 60 | female | 1 | 58 | 7 | 8 | carboplatin + paclitaxel + pembrolizumab | 8.1 | false | MSS | 2026-03-15T05:35:57.132665+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_900954 | REC_0001178 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 19 | 14.6 | 66 | female | 1 | 19 | 5.4 | 6 | osimertinib 80 mg daily | 9.5 | true | MSS | 2026-03-15T05:35:57.132898+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_639613 | REC_0001179 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None | 28 | 7.4 | 73 | female | 1 | 49 | 5.4 | 2 | carboplatin + paclitaxel + pembrolizumab | 14.6 | false | MSS | 2026-03-15T05:35:57.133125+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_410110 | REC_0001180 | Non-small cell lung cancer | Adenocarcinoma | IVA | ROS1 fusion | 23 | 12.8 | 70 | male | 2 | 14 | 4 | 1 | entrectinib 600 mg daily | 21.1 | false | MSI-H | 2026-03-15T05:35:57.133365+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_622182 | REC_0001181 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 27 | 9.3 | 63 | female | 0 | 16 | 4.5 | 4 | alectinib 600 mg BID | 13.2 | false | MSS | 2026-03-15T05:35:57.133595+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_454395 | REC_0001182 | Non-small cell lung cancer | Large cell carcinoma | IVA | None (PD-L1 high) | 19 | 5.2 | 69 | female | 1 | 10 | 5.7 | 3 | pembrolizumab 200 mg q3w | 17.4 | false | MSS | 2026-03-15T05:35:57.133822+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_788124 | REC_0001183 | Non-small cell lung cancer | Adenocarcinoma | IVA | ROS1 fusion | 17 | 11.2 | 71 | female | 2 | 12 | 7.9 | 1 | entrectinib 600 mg daily | 22.3 | false | MSI-H | 2026-03-15T05:35:57.134054+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_319799 | REC_0001184 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 23 | 4.3 | 71 | female | 2 | 74 | 6.4 | 6 | carboplatin + paclitaxel + pembrolizumab | 8.7 | true | MSS | 2026-03-15T05:35:57.134322+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_546383 | REC_0001185 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 27 | 12.1 | 67 | female | 0 | 3 | 4 | 5 | entrectinib 600 mg daily | 12.6 | false | MSI-H | 2026-03-15T05:35:57.134560+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_187530 | REC_0001186 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 26 | 7.9 | 71 | female | 1 | 11 | 3.8 | 7 | sotorasib 960 mg daily | 5.6 | false | MSS | 2026-03-15T05:35:57.134791+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_782568 | REC_0001187 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 31 | 7.7 | 74 | female | 2 | 11 | 4.7 | 8 | alectinib 600 mg BID | 15.2 | false | MSS | 2026-03-15T05:35:57.135024+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_244194 | REC_0001188 | Non-small cell lung cancer | Adenocarcinoma | IVA | ALK fusion | 22 | 9.7 | 74 | female | 1 | 7 | 4.8 | 1 | alectinib 600 mg BID | 12 | false | MSS | 2026-03-15T05:35:57.135250+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_222994 | REC_0001189 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR L858R | 23 | 14.2 | 71 | female | 1 | 15 | 4.1 | 2 | osimertinib 80 mg daily | 9.6 | false | MSS | 2026-03-15T05:35:57.135479+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_294651 | REC_0001190 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 32 | 15.6 | 61 | male | 0 | 16 | 3.7 | 6 | osimertinib 80 mg daily | 16.4 | true | MSI-H | 2026-03-15T05:35:57.135715+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_789030 | REC_0001191 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None (PD-L1 high) | 32 | 5.5 | 72 | male | 2 | 44 | 5.2 | 3 | pembrolizumab 200 mg q3w | 4 | true | MSS | 2026-03-15T05:35:57.135946+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_533320 | REC_0001192 | Non-small cell lung cancer | Adenocarcinoma | IVA | KRAS G12C | 31 | 12 | 58 | female | 0 | 0 | 6.8 | 2 | sotorasib 960 mg daily | 16.5 | true | MSI-H | 2026-03-15T05:35:57.136285+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_747725 | REC_0001193 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 21 | 12 | 74 | male | 2 | 16 | 6.4 | 7 | alectinib 600 mg BID | 10.1 | true | MSS | 2026-03-15T05:35:57.136536+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_470270 | REC_0001194 | Non-small cell lung cancer | Adenocarcinoma | IVA | ALK fusion | 25 | 9.3 | 66 | female | 0 | 12 | 6.2 | 1 | alectinib 600 mg BID | 31.2 | true | MSS | 2026-03-15T05:35:57.136765+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_584984 | REC_0001195 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 25 | 9.5 | 72 | female | 1 | 48 | 4.7 | 4 | carboplatin + paclitaxel + pembrolizumab | 5.8 | false | MSS | 2026-03-15T05:35:57.136994+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_693188 | REC_0001196 | Non-small cell lung cancer | Adenocarcinoma | IVB | None (PD-L1 high) | 30 | 10.1 | 75 | female | 1 | 14 | 4.7 | 5 | pembrolizumab 200 mg q3w | 8 | true | MSI-H | 2026-03-15T05:35:57.137229+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_235460 | REC_0001197 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 23 | 9.1 | 62 | female | 0 | 20 | 6.3 | 6 | carboplatin + paclitaxel + pembrolizumab | 9 | false | MSS | 2026-03-15T05:35:57.137509+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_785782 | REC_0001198 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 27 | 13.7 | 71 | female | 2 | 13 | 7.2 | 4 | sotorasib 960 mg daily | 14.7 | true | MSS | 2026-03-15T05:35:57.137743+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_501444 | REC_0001199 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR exon 19 deletion | 25 | 18.4 | 63 | male | 1 | 6 | 3.3 | 2 | osimertinib 80 mg daily | 16.8 | true | MSS | 2026-03-15T05:35:57.137980+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_918552 | REC_0001200 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 26 | 8.3 | 66 | female | 0 | 8 | 4.2 | 7 | sotorasib 960 mg daily | 13.7 | true | MSS | 2026-03-15T05:35:57.138208+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.